2.70
Schlusskurs vom Vortag:
$2.83
Offen:
$2.88
24-Stunden-Volumen:
7.22M
Relative Volume:
1.53
Marktkapitalisierung:
$340.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-258.08M
KGV:
-0.9818
EPS:
-2.75
Netto-Cashflow:
$-202.32M
1W Leistung:
-7.85%
1M Leistung:
-60.58%
6M Leistung:
-76.64%
1J Leistung:
-87.05%
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Vergleichen Sie RCKT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RCKT
Rocket Pharmaceuticals Inc
|
2.70 | 340.45M | 0 | -258.08M | -202.32M | -2.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-30 | Herabstufung | Evercore ISI | Outperform → In-line |
2025-05-28 | Herabstufung | Goldman | Neutral → Sell |
2025-05-28 | Herabstufung | JP Morgan | Overweight → Neutral |
2025-05-28 | Herabstufung | Jefferies | Buy → Hold |
2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2025-05-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2025-05-27 | Herabstufung | Needham | Buy → Hold |
2025-05-27 | Herabstufung | TD Cowen | Buy → Hold |
2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
2024-12-30 | Eingeleitet | Wedbush | Outperform |
2024-12-18 | Eingeleitet | Jefferies | Buy |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-04-02 | Eingeleitet | Goldman | Neutral |
2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
2022-11-01 | Eingeleitet | BTIG Research | Buy |
2022-07-08 | Eingeleitet | Raymond James | Outperform |
2021-10-20 | Fortgesetzt | Cowen | Outperform |
2021-03-02 | Eingeleitet | Stifel | Buy |
2021-02-18 | Eingeleitet | Needham | Buy |
2020-12-16 | Eingeleitet | UBS | Buy |
2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
2020-07-02 | Eingeleitet | JP Morgan | Overweight |
2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Investors who lost money with shares of Rocket Pharmaceuticals, - openPR.com
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Benzinga
Rocket Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $5.00 at UBS Group - Defense World
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Analyst | - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire
UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating - MarketScreener
UBS Adjusts Price Target for Rocket Pharmaceuticals (RCKT) Amid Program Developments | RCKT Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. LawsuitRCKT - PR Newswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph
Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - GuruFocus
Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - ACCESS Newswire
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - marketscreener.com
RCKT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RCKT Investor Notice: Robbins LLP Reminds Shareholders of - GlobeNewswire
Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead By Investing.com - Investing.com South Africa
Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead - Investing.com Australia
RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Rocket - GlobeNewswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025Contact Levi & Korsinsky - ACCESS Newswire
ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - TradingView
RCKT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - ACCESS Newswire
Contact Levi & Korsinsky by August 11, 2025 Deadline to - GlobeNewswire
RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Business Wire
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy TrialHagens Berman - PR Newswire
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc.(RCKT) - PR Newswire
Join Class Action to Recover Losses From Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - ACCESS Newswire
Join Class Action to Recover Losses from Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - ACCESS Newswire
Shareholder Alert: Robbins LLP Informs Investors of the Rocket Pharmaceuticals, Inc. Class Action - Eastern Progress
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - PR Newswire
August 11, 2025 Deadline Approaching: Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky - ACCESS Newswire
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class - GlobeNewswire
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman - TradingView
Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - GlobeNewswire
Securities Fraud Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT)Levi & Korsinsky Reminds Investors of August 11, 2025 - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
RCKT’s 2023 Market Dance: Down -73.91% – Time to Invest? - investchronicle.com
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Forecasts RCKT FY2026 Earnings - Defense World
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rocket Pharmaceuticals Inc-Aktie (RCKT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Schwartz Jonathan David | See Remarks |
May 20 '25 |
Sale |
6.45 |
801 |
5,163 |
235,255 |
Patel Kinnari | See Remarks |
May 20 '25 |
Sale |
6.45 |
767 |
4,944 |
441,927 |
Shah Gaurav | CEO |
May 20 '25 |
Sale |
6.45 |
2,253 |
14,523 |
786,806 |
Wilson Martin | General Counsel |
May 20 '25 |
Sale |
6.45 |
587 |
3,784 |
149,163 |
Militello John | See Remarks |
May 16 '25 |
Sale |
6.53 |
655 |
4,276 |
64,384 |
Patel Kinnari | See Remarks |
May 16 '25 |
Sale |
6.53 |
1,409 |
9,198 |
442,694 |
Schwartz Jonathan David | See Remarks |
May 16 '25 |
Sale |
6.53 |
1,582 |
10,327 |
236,056 |
Shah Gaurav | CEO |
May 16 '25 |
Sale |
6.53 |
3,621 |
23,638 |
789,059 |
Wilson Martin | General Counsel |
May 16 '25 |
Sale |
6.53 |
946 |
6,175 |
149,750 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):